Show simple item record

Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer

hal.structure.identifierIowa State University [ISU]
dc.contributor.authorSCHNEIDER, Benjamin
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorBOYER, Arnaud
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorCICCOLINI, Joseph
hal.structure.identifierService d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
dc.contributor.authorBARLESI, Fabrice
hal.structure.identifierMayo Clinic [Rochester]
dc.contributor.authorWANG, Kenneth
hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
dc.contributor.authorBENZEKRY, Sébastien
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorMOCHEL, Jonathan
dc.date.accessioned2024-04-04T03:01:18Z
dc.date.available2024-04-04T03:01:18Z
dc.date.issued2019-04-19
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/192889
dc.description.abstractEnBevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BE V- PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulationssuggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap.
dc.language.isoen
dc.publisherAmerican Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics
dc.subject.enCancers
dc.subject.enOptimization
dc.subject.enOncology
dc.subject.enPharmacokinetics-pharmacodynamics
dc.subject.enMathematical modeling
dc.title.enOptimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer
dc.typeArticle de revue
dc.identifier.doi10.1002/psp4.12415
dc.subject.halInformatique [cs]/Modélisation et simulation
dc.subject.halSciences du Vivant [q-bio]/Cancer
dc.subject.halPhysique [physics]/Physique [physics]/Analyse de données, Statistiques et Probabilités [physics.data-an]
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
dc.subject.halStatistiques [stat]/Applications [stat.AP]
bordeaux.journalCPT: Pharmacometrics and Systems Pharmacology
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
hal.identifierhal-02109335
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-02109335v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CPT:%20Pharmacometrics%20and%20Systems%20Pharmacology&rft.date=2019-04-19&rft.au=SCHNEIDER,%20Benjamin&BOYER,%20Arnaud&CICCOLINI,%20Joseph&BARLESI,%20Fabrice&WANG,%20Kenneth&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record